PS-341 (Bortezomib) inhibits proliferation and induces apoptosis of megakaryoblastic MO7-e cells

Leukemia Research

Volumn 32, Issue 1, 2008, Pages 103-112

  Galimberti, S ^a   Canestraro, M ^a   Pacini, S ^a   Fazzi, R ^a   Orciuolo, E ^a   Trombi, L ^a   Mattii, L ^b   Battolla, B ^b   Capodanno, A ^c   Collecchi, P ^c   Veroni, F ^d   Simi, P ^d   Piaggi, S ^b   Casini, A ^b   Petrini, M ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF PISA   (Italy)

^c Division of Pathology   (Italy)

^d UNIVERSITY HOSPITAL OF PISA   (Italy)

Author keywords

Apoptosis; Bortezomib; Megakaryoblastic leukemia; NF B; PS 341; WT1

Indexed keywords

BORTEZOMIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEASOME; PROTEASOME INHIBITOR; WT1 PROTEIN;

ACUTE MEGAKARYOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL LINE; CONCENTRATION RESPONSE; CONTROLLED STUDY; HUMAN; HUMAN CELL; IC 50; LEUKEMIA CELL LINE; MEGAKARYOBLAST; PRIORITY JOURNAL; PROTEIN DEGRADATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BORONIC ACIDS; CELL CYCLE; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION; GENES, WILMS TUMOR; HUMANS; LEUKEMIA, MEGAKARYOBLASTIC, ACUTE; MYELOFIBROSIS; PROTEASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PYRAZINES;

EID: 36148997631     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2007.05.023     Document Type: Article

References (37)

1. Cortes J., Thomas D., Koller C., et al. Phase I study of bortezomib in refractory or relapsed acute leukemias. Clin Cancer Res 10 (2004) 3371-3376
2. Boccadoro M., Morgan G., and Cavenagh J. Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy. Cancer Cell Int 5 (2005) 18-26
3. Kim J.Y., Lee S., Hwangbo B., et al. NF-kappaB activation is related to the resistance of lung cancer cells to TNF-alpha-induced apoptosis. Biochem Biophys Res Commun 273 (2000) 140-146
4. Kordes U., Krappmann D., Heissmeyer V., Ludwig W.D., and Scheidereit C. Transcription factor NF-kappaB is constitutively activated in acute lymphoblastic leukemia cells. Leukemia 14 (2000) 399-402
5. Komura E., Tonetti C., Penard-Lacronique V., et al. Role for the nuclear factor kappaB pathway in transforming growth factor-beta1 production in idiopathic myelofibrosis: possible relationship with FK506 binding protein 51 overexpression. Cancer Res 65 (2005) 3281-3289
6. Tefferi A., and Silverstein M.N. Current perspective in agnogenic myeloid metaplasia. Leuk Lymphoma 22 Suppl. 1 (1996) 169-171
7. Sato Y., Suda T., Suda J., et al. Multilineage expression of haemopoietic precursors with an abnormal clone in idiopathic myelofibrosis. Br J Haematol 64 (1986) 657-667
8. Martyre' M.C. TGF-beta and megakaryocytes in the pathogenesis of myelofibrosis in myeloproliferative disorders. Leuk Lymphoma 20 (1995) 39-44
9. Rameshwar P., Chang V.T., and Gascon P. Implication of CD44 in adhesion-mediated overproduction of TGF-beta and IL-1 in monocytes from patients with bone marrow fibrosis. Br J Haematol 93 (1996) 22-29
10. Rameshwar P., Narayanan R., Qian J., Denny T.N., Colon C., and Gascon P. NF-kappa B as a central mediator in the induction of TGF-beta in monocytes from patients with idiopathic myelofibrosis: an inflammatory response beyond the realm of homeostasis. J Immunol 165 (2000) 2271-2277
11. Tefferi A. Pathogenesis of myelofibrosis with myeloid metaplasia. J Clin Oncol 23 (2005) 8520-8530
12. Hideshima T., Richardson P.G., and Anderson K.C. Targeting proteasome inhibition in hematologic malignancies. Rev Clin Exp Hematol 7 (2003) 191-204
13. Chauhan D., Li G., Hideshima T., et al. JNK-dependent release of mitochondrial protein, Smac, during apoptosis in multiple myeloma (MM) cells. J Biol Chem 278 (2003) 17593-17596
14. Chauhan D., Li G., Sattler M., et al. Superoxide-dependent and -independent mitochondrial signaling during apoptosis in multiple myeloma cells. Oncogene 22 (2003) 6296-6300
15. Mitsiades N., Mitsiades C.S., Richardson P.G., et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 101 (2003) 2377-2380
16. Yang Y., Ikezoe T., Saito T., Kobayashi M., Koeffler H.P., and Taguchi H. Proteasome inhibitor PS-341 induces growth arrest and apoptosis of non-small cell lung cancer cells via the JNK/c-Jun/AP-1 signaling. Cancer Sci 95 (2004) 176-180
17. Teicher B.A., Ara G., Herbst R., Palombella V.J., and Adams J. The proteasome inhibitor PS-341 in cancer therapy. Clin Cancer Res 5 (1999) 2638-2645
18. Bross P.F., Kane R., Farrell A.T., et al. Approval summary for bortezomib for injection in the treatment of multiple myeloma. Clin Cancer Res 10 (2004) 3954-3964
19. Fazzi R., Pacini S., Testi R., et al. Carboxy-terminal fragment of osteogeneic growth peptide in vitro increases bone marrow cell density in idiopathic myelofibrosis. Br J Haematol 121 (2003) 76-85
20. Dehbi M., Hiscott J., and Pelletier J. Activation of the wt1 Wilms' tumor suppressor gene by NF-kappaB. Oncogene 16 (1998) 2033-2039
21. Sanz C., Richard C., Prosper F., and Fernandez-Luna J.L. Nuclear factor k B is activated in myelodysplastic bone marrow cells. Haematologica 87 (2002) 1005-1006
22. Testi R., Mattii L., Di Simone D., et al. Evaluation of resistance index of several anticancer agents on parental and resistant P-388 cell lines. Leuk Res 19 (1995) 257-261
23. Galimberti S., Guerrini F., Carulli G., et al. Significant co-expression of WT1 and MDR1 genes in acute myeloid leukemia patients at diagnosis. Eur J Haematol 72 (2004) 45-51
24. Voorhees P.M., Dees E.C., O'Neil B., and Orlowski R.Z. The proteasome as a target for cancer therapy. Clin Cancer Res 9 (2003) 6316-6325
25. Goy A., Younes A., McLaughlin P., et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 23 (2005) 667-675
26. Guzman M.L., Neering S.J., Upchurch D., et al. Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood 98 (2001) 2301-2307
27. Yu C., Rahmani M., Conrad D., Subler M., Dent P., and Grant S. The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571. Blood 102 (2003) 3765-3774
28. Barosi G., and Hoffman R. Idiopathic myelofibrosis. Semin Hematol 42 (2005) 248-258
29. Mayo M.W., and Baldwin A.S. The transcription factor NF-kappaB: control of oncogenesis and cancer therapy resistance. Biochim Biophys Acta 1470 (2000) M55-M62
30. Cilloni D., Gottardi E., De Micheli D., et al. Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients. Leukemia 16 (2002) 2115-2121
31. Ogawa H., Tamaki H., Ikegame K., et al. The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia. Blood 101 (2003) 1698-1704
32. Na I.K., Kreuzer K.A., Lupberger J., Dorken B., and le Coutre P. Quantitative RT-PCR of Wilms tumor gene transcripts (WT1) for the molecular monitoring of patients with accelerated phase bcr/abl + CML. Leuk Res 29 (2005) 343-345
33. Cilloni D., Messa F., Gottardi E., et al. Sensitivity to imatinib therapy may be predicted by testing Wilms tumor gene expression and colony growth after a short in vitro incubation. Cancer 101 (2004) 979-988
34. Guglielmelli P., Manfredini M., Zini R., et al. Characterization of differentially expressed genes in CD34+ cells from peripheral blood of idiopathic myelofibrosis patients using microarray analysis. Haematologica 90 Suppl. 3 (2005) 245
35. Jones L.C., Tefferi A., Vuong P.T., Desmond J.C., Hofmann W.K., and Koeffler H.P. Detection of aberrant gene expression in CD34+ hematopoietic stem cells from patients with agnogenic myeloid metaplasia using oligonucleotide microarrays. Stem Cells 23 (2005) 631-637
36. Lauricella M., Emanuele S., D'Anneo A., et al. Tesoriere GJNK and AP-1 mediate apoptosis induced by bortezomib in HepG2 cells via FasL/caspase-8 and mitochondria-dependent pathways. Apoptosis 11 (2006) 607-625
37. Zheng B., Georgakis G.V., Li Y., et al. Induction of cell cycle arrest and apoptosis by the proteasome inhibitor PS-341 in Hodgkin disease cell lines is independent of inhibitor of nuclear factor-kappaB mutations or activation of the CD30, CD40, and RANK receptors. Clin Cancer Res 10 (2004) 3207-3215